Australian Prescriber最新文献

Mavacamten for symptomatic obstructive hypertrophic cardiomyopathy.

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.006

引用次数: 0

The role of triple antithrombotic therapy in patients with atrial fibrillation and coronary stent insertion.

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.009

Kate Ziser, Saqib Rahman, Reham Soro, Nazanin Falconer, Danielle Harrop

{"title":"The role of triple antithrombotic therapy in patients with atrial fibrillation and coronary stent insertion.","authors":"Kate Ziser, Saqib Rahman, Reham Soro, Nazanin Falconer, Danielle Harrop","doi":"10.18773/austprescr.2025.009","DOIUrl":"10.18773/austprescr.2025.009","url":null,"abstract":"Triple antithrombotic therapy or 'triple therapy' describes the combination of 3 oral antithrombotic medications - an anticoagulant drug (warfarin, apixaban, rivaroxaban or dabigatran) and 2 antiplatelet drugs (usually aspirin plus clopidogrel). Most commonly, triple therapy is indicated for patients who require both dual antiplatelet therapy following coronary stent insertion for acute coronary syndrome and long-term anticoagulation for atrial fibrillation. Current evidence supports shorter durations of triple therapy to mitigate bleeding risks without compromising ischaemic protection. Recent guidelines advocate up to 1 week of triple therapy for most patients, extending up to 1 month for those at high ischaemic risk. In practice, the approach to antithrombotic therapy is individualised by the patient's cardiologist, balancing bleeding and ischaemic risks. General practitioners and pharmacists have an important role in supporting patients in their step-down plan to dual therapy with the oral anticoagulant drug and one of the antiplatelet drugs, and then ongoing monotherapy with the oral anticoagulant drug.","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 1","pages":"18-22"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11875729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Propranolol overdose following prescription for anxiety.

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.005

Evan Browne, Jacqueline Huber, Bridin Murnion

引用次数: 0

Australian Prescriber: celebrating 50 years of growth and change.

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.007

Rosie Scott

引用次数: 0

New drug comments: aiming to deliver useful, timely, independent information for health professionals.

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.002

Tilenka Thynne, Rohan Elliott

引用次数: 0

Teclistamab for relapsed or refractory multiple myeloma.

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.001

引用次数: 0

Device-assisted therapies for Parkinson disease.

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.003

Nadia Mouchaileh, Jillian Cameron

{"title":"Device-assisted therapies for Parkinson disease.","authors":"Nadia Mouchaileh, Jillian Cameron","doi":"10.18773/austprescr.003","DOIUrl":"10.18773/austprescr.003","url":null,"abstract":"Device-assisted therapies for Parkinson disease include apomorphine continuous subcutaneous infusion, levodopa continuous intestinal gel infusion, levodopa continuous subcutaneous infusion and deep brain stimulation. These therapies have a role in managing motor fluctuations and dyskinesias in people with advanced Parkinson disease when symptoms are inadequately controlled with oral and transdermal treatments. Subcutaneous infusion of apomorphine or levodopa are the least invasive device-assisted therapies. Levodopa intestinal infusion is delivered via a surgically placed intestinal tube. Deep brain stimulation involves implanting electrodes into specific target regions of the basal ganglia to modulate brain activity. Selecting an appropriate device-assisted therapy depends on individual factors such as age, comorbidities, symptom severity and patient preferences. Initiation and management require neurologist and multidisciplinary involvement, typically in a specialist movement disorder centre. Primary care clinicians play a crucial role in ongoing support and management for people using these therapies, including monitoring and managing adverse effects and communicating with movement disorder services.","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 1","pages":"10-17"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11875732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Etrasimod for moderate to severe ulcerative colitis.

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.004

引用次数: 0

Drug safety in pregnancy.

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.008

Debra Kennedy, Ronald Batagol

引用次数: 0

Pharmacovigilance in Australia: how do adverse event reports from clinicians contribute to medicine and vaccine safety? 澳大利亚的药物警戒：临床医生的不良事件报告如何促进药物和疫苗安全？

IF 3.4

Australian Prescriber Pub Date : 2024-12-01 DOI: 10.18773/austprescr.2024.056

Deborah Greenbaum, Stephanie Cheung, Claire Turner, Fiona Mackinnon, Claire Larter

{"title":"Pharmacovigilance in Australia: how do adverse event reports from clinicians contribute to medicine and vaccine safety?","authors":"Deborah Greenbaum, Stephanie Cheung, Claire Turner, Fiona Mackinnon, Claire Larter","doi":"10.18773/austprescr.2024.056","DOIUrl":"https://doi.org/10.18773/austprescr.2024.056","url":null,"abstract":"Reporting adverse events (adverse drug reactions) associated with medicines and vaccines assists with identifying previously unrecognised side effects and other safety concerns. Reporting adverse events to the Therapeutic Goods Administration is mandatory for sponsors (pharmaceutical companies), and strongly encouraged but voluntary for healthcare professionals and consumers. Adverse events should be reported even when causality is uncertain, as reports may contribute to identification of a safety signal for new or uncommon events. Suspected adverse events associated with new medicines and vaccines (registered in the last 5 years), and medicines included in the Black Triangle Scheme, should be prioritised for reporting. For other medicines, serious adverse events and unexpected adverse events should be prioritised. The Therapeutic Goods Administration analyses adverse event reporting data and uses signal detection methods to identify and evaluate emerging safety signals, which may lead to regulatory actions and communication to address safety issues.","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 6","pages":"186-191"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0